Stay updated on Nivolumab Plus Ipilimumab Neoadjuvant Therapy Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab Neoadjuvant Therapy Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab Neoadjuvant Therapy Clinical Trial page
- Check7 days agoChange DetectedTaoyuan District, Taiwan was removed from the study locations and Taoyuan, Taiwan was added, clarifying the site in Taoyuan. This updates the geographic listing of trial sites.SummaryDifference0.1%

- Check15 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a minor administrative release for the ClinicalTrials.gov site.SummaryDifference0.1%

- Check22 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedPublication added under Publications: Lancet Oncology 2024 article on pathological response following neoadjuvant immune checkpoint inhibitors in hepatocellular carcinoma (HCC).SummaryDifference0.1%

- Check50 days agoChange DetectedAdded Hepatocellular carcinoma as a condition term and a Genetics and Rare Diseases Information Center resource. The site footer revision updated from v3.4.3 to v3.5.0.SummaryDifference0.2%

- Check65 days agoChange DetectedFooter revision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Plus Ipilimumab Neoadjuvant Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab Neoadjuvant Therapy Clinical Trial page.